In the BioHarmony Drug Report Database
Methylnaltrexone
Relistor (methylnaltrexone) is a small molecule pharmaceutical. Methylnaltrexone was first approved as Relistor on 2008-04-24. It is used to treat constipation in the USA. It has been approved in Europe to treat constipation and opioid-related disorders. The pharmaceutical is active against mu-type opioid receptor. In addition, it is known to target kappa-type opioid receptor and delta-type opioid receptor. Relistor’s patents are valid until 2031-03-10 (FDA).
Trade Name
|
Relistor |
|---|---|
Common Name
|
methylnaltrexone |
ChEMBL ID
|
CHEMBL1186579 |
Indication
|
constipation, opioid-related disorders |
Drug Class
|
Narcotic agonists/antagonists (normorphine type) |
Image (chem structure or protein)